Ompenaclid succinate is under clinical development by Inspirna and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ompenaclid succinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ompenaclid succinate overview
Ompenaclid succinate (RGX-202) is under development for the treatment of metastatic colorectal cancer. The drug candidate is administered through oral route.It acts by targeting SLC6a8.It is based on Rgenix technology. It was also under development for the treatment of colon cancer, lung cancer, lymphoma and metastasis to the liver, adenocarcinoma of the gastroesophageal junction, pancreatic cancer, biliary tumor, small intestine cancer, relapsed and refractory gastrointestinal tumors.
Inspirna, formerly Rgenix Inc is a clinical-stage biopharmaceutical company that develops novel drugs that target key pathways in cancer progression. The company’s lead drug candidate RGX-104, is a small molecule immunotherapy which targets the immune system to treat cancer progression. Its pipeline drug candidates include RGX-202, a small molecule that inhibits a novel cancer metabolism. Inspirna also discovers several novel cancer targets that drive tumor growth and cancer progression. The company also develops drugs for lung cancer, colorectal cancer, glioblastoma and triple-negative breast cancer, among others. It also conducts multiple programs in the preclinical development of drugs in the field of oncology. Inspirna is headquartered in New York City, New York, the US.
For a complete picture of Ompenaclid succinate’s drug-specific PTSR and LoA scores, buy the report here.